[Skip to Content]
[Skip to Content Landing]
Citations 0
April 21, 2010

Contraindicated Medication Use in Dialysis Patients—Reply

JAMA. 2010;303(15):1481-1482. doi:10.1001/jama.2010.444

In Reply: We agree with Drs Deal and Hollands that the FDA-directed labeling for enoxaparin dosing in dialysis patients undergoing percutaneous coronary intervention is vague. The FDA revised the content and format of prescription drug labeling in 2006 to make prescribing information clearer and more concise.1 Yet, although eptifibatide and enoxaparin are both predominantly renally cleared and both associated with increased bleeding complications in patients undergoing dialysis, the FDA-directed labeling of the 2 drugs is quite different.

First Page Preview View Large
First page PDF preview
First page PDF preview